the peach is back

Frodo was basically an innocent puppy thrown into the Torment Nexus so that EVERYONE ELSE could maybe have a hope of surviving. And he did that willingly. HE DID IT OF HIS OWN FREE WILL, KNOWING IT WOULD RUIN HIM.

"For millions of people managing type 2 diabetes, mornings begin the same way — a needle, a dose, and a quiet mental note to do it all again tomorrow.

That routine just changed.

On March 26, 2026, the U.S. Food and Drug Administration approved Awiqli (insulin icodec-abae), developed by Novo Nordisk, as the first and only once-weekly basal insulin ever approved for adults with type 2 diabetes in the United States.

This is not a minor update to an existing drug.

It is the first entirely new class of basal insulin to reach U.S. patients in more than two decades.

Instead of injecting insulin every single day, people with type 2 diabetes using Awiqli will only need one shot per week, on the same day, every week.

That means reducing from 365 injections a year down to just 52.

For anyone who has ever felt the weight of that daily ritual — the anxiety of forgetting, the physical discomfort, the constant reminder that their body needs help — this approval represents something much bigger than a dosing schedule.

It represents relief.

How the Drug Actually Works

Understanding why this injection lasts a full week requires a quick look inside the body.

Most traditional basal insulins are absorbed into the bloodstream and begin breaking down within 24 hours, which is why patients need a fresh dose every day to maintain stable blood sugar levels.

Awiqli works differently.

Its active ingredient, insulin icodec-abae, is engineered to loosely attach to a blood protein called albumin, which is found naturally and abundantly in the bloodstream.

This attachment creates a slow-release reservoir.

Instead of flooding the system and fading fast, the insulin releases gradually and consistently over an entire seven-day period, keeping blood sugar in a healthy range around the clock...

The FDA reviewed and ultimately declined to approve it for people with type 1 diabetes, citing concerns about a modestly increased risk of hypoglycemia in that population specifically.

Some regulatory agencies in other countries, including the European Union, Canada, Australia, and Japan, have approved Awiqli for both type 1 and type 2 diabetes, but for now the U.S. approval is limited to type 2...

What Comes Next

Awiqli is not standing alone in this space for long.

Eli Lilly is developing its own once-weekly basal insulin, called efsitora alfa, which is currently in late-stage clinical trials.

If that drug also earns FDA approval, it would give patients and doctors two once-weekly options to choose from, allowing for personalized decisions based on a patient’s health profile, insurance coverage, and individual response.

The broader direction of travel in diabetes care is unmistakable.

Fewer injections, smarter formulations, and better integration with digital tools like continuous glucose monitors and insulin-tracking apps are all converging toward a future where managing diabetes requires less daily mental effort without becoming any less medically precise...

A Small Shot With Large Implications

It is easy to look at a once-weekly injection and see only a scheduling change.

But the science behind Awiqli, the scale of the ONWARDS trials, and the consistent satisfaction reported by patients all point toward something that matters far more than convenience.

Diabetes management has always asked a lot of people.

It asks for daily vigilance, daily discipline, and a daily willingness to confront one’s own condition, sometimes in uncomfortable or inconvenient circumstances.

Anything that reduces that load, without reducing the quality of care, is worth taking seriously.

For the more than 37 million Americans living with diabetes, and the hundreds of millions more around the world, a simpler weekly routine could mean the difference between a treatment plan that works on paper and one that actually works in a person’s life.

That is the real significance of what the FDA approved on March 26, 2026.

Not just a new drug.

A new way of keeping people healthy, one week at a time."

It took less than 5 minutes to switch to a ProtonMail account, less than 2 hours to download and/or offload every byte of data from my Google account, and less than 3 days to change every single account or service I've ever signed up for to the new address.

As of today, the only single one I have that's still tied to it is YouTube. It's the only thing I'd lose access to if I deleted my Google acount entirely.

They really, really want you to believe that it's a hassle to switch to a different email system. But it's not. Most websites and/or services allow you to change the email address associated with it.

You can and should switch to a free, encrypted Proton email account. You also get all of the below perks. For free. There is no trick. It is paid for by the people with paying plans. I am one of them. The (completely functional) free tier is there to entice you into getting a paid account with even more perks. (It worked on me.) But there's no penalty or pressure for staying with the free account.

Also get your stuff off the google drive and put it on Proton's drive. It is encrypted. Only you with your password can access it. Not even Proton can see what you put in there.

The Bitch Is Back, Elton John

Book that was bad: this sucked 👎

The European Union already forced Apple to abandon its proprietary charging port and adopt USB-C across its entire iPhone lineup. It just did something bigger. A new EU mandate requires every smartphone sold in Europe including Apple devices to feature a battery that can be replaced by the user without specialist tools, without voiding a warranty, and without sending the device to a manufacturer approved service center. Batteries must maintain a minimum capacity threshold after a set number of charge cycles and replacement parts must remain available for up to ten years after a model goes on sale.

The consumer electronics industry built its current business model around batteries that degrade, cannot be replaced at home, and create a natural upgrade cycle every two to three years. The EU just legislated that model out of existence in the world's largest regulatory market.

Apple, Samsung, and every other manufacturer now faces a choice between redesigning their devices for the European market or accepting that their current hardware architecture is no longer legally sellable there.